biocompatibility testing of "biomaterials"
Post on 11-Aug-2015
162 Views
Preview:
TRANSCRIPT
Biocompatibilit
y
Testing
Swapnil Singh, NIPER, Mohali
IntroductionAcceptance of an artificial implant by the surrounding tissues and by the body as a whole
The ability of a material to perform its desired function with respect to a medical therapy, without eliciting any undesirable local or systemic effects in the recipient or beneficiary of that therapy, but generating the most appropriate beneficial cellular or tissue response in that specific situation, and optimizing the clinically relevant performance of that therapy (Williams, 2008)
A material is considered “biocompatible” if it allows the body to function without complications like allergic reactions or adverse side effects. Biocompatibility is the “suitability” of a material for exposure to the body or bodily fluids
1
When lacking biocompatiblity…
long-lasting chronic inflammation
cytotoxic chemicals
disruption of cells at interface
micron-sized materials
irritation
corrosion of metals
restenosis/thrombosis
Plan of biocompatibility tests
in vitro tests Animal experiments Clinical tests
•Evaluation under in vitro (literally “in glass”) conditions can provide rapid and inexpensive data on biological interaction
•Will the in vitro test measure parameters relevant to what will occur in the much more complex in vivo environment?
•in vitro tests minimize the use of animals in research, a desirable goal
2
Contd..
•When appropriately used, in vitro testing provides useful insights that can dictate whether a device need be further evaluated in expensive in vivo experimental models
•The common approach is to start with simple in vitro tests
•If these experiments and investigations of a material’s efficiency deliver promising findings, then more comprehensive studies on experimental animals (in vivo evaluation) will be performed
•Clinical trials are the final step of this evaluation process
3
in vitro tests•Less expensive way
•Simulate biological reactions to materials when they are placed on or into tissues of the body
ADVANTAGE• Experimentally controllable, repeatable, • Fast, relatively inexpensive, relatively simple.• Avoid the ethical and legal issues• Transgenic cells carrying human genes can be used• Small amount of test material is required
DISADVANTAGE• Questionable clinical relevance• Chronic effects cannot be tested• Pharmacokinetics cannot be evaluated
4
in vivo tests •The goal is to determine the biocompatibility or safety in a biological environment
•Carried out to determine that the device performs as intended and presents no significant harm to the patient or user
ADVANTAGES• Higher level of significance • Simulate real body conditions
DISADVANTAGES• Expensive• Time consuming • Ethical issues 5
Factors considered during in vivo test
•Chemical composition of the materials
•Nature, degree, frequency, and
•Duration of exposure of the device and its constituents to the intended tissues
6
Selection of in vivo tests
To facilitate the selection of appropriate tests biomaterials can be categorized by
Nature of body contact of the medical device and by
Duration of contact of the medical device
7
TABLE 1 Medical Device Categorization by Tissue Contact and Contact Duration
Surface devices SkinMucosal membranesBreached or compromised surfaces
External communicatingdevices
Blood path, indirectTissue/bone/dentin communicatingCirculating blood
Implant devices Tissue/boneBlood
Contact duration Limited, ≤24 hoursProlonged, >24 hours and <30 daysPermanent, >30 days
Two perspectives in in vivo testing
1. Utilization of in vivo tests to determine the general biocompatibility of newly developed biomaterials for which some knowledge of the tissue compatibility is necessary for further research and development
2. It focuses on the biocompatibility of the final product, that is, the medical device in the condition in which it is to be implanted
10
Various in vivo Tests as per ISO 10993 standard and the FDA guidance document are:
in vivo tests
11
13
ISO 10,993-1. Evaluation and testingISO 10,993-2. Animal welfare requirementsISO 10,993-3. Tests for genotoxicity, carcinogenicity,and reproductive toxicityISO 10,993-4. Selection of tests for interactionswith bloodISO 10,993-5. Tests for cytotoxicity: In vitro methodsISO 10,993-6. Tests for local effects after implantationISO 10,993-7. Ethylene oxide sterilization residualsISO 10,993-9. Framework for the identificationand quantification of potentialdegradation productsISO 10,993-10. Tests for irritation and sensitizationISO 10,993-11. Tests for systemic toxicityISO 10,993-12. Sample preparation and referencematerialsISO 10,993-13. Identification and quantification ofdegradation products from polymersISO 10,993-14. Identification and quantification ofdegradation products from ceramicsISO 10,993-15. Identification and quantification ofdegradation products from metalsand alloysISO 10,993-16. Toxicokinetic study design fordegradation products and leachables
ISO 10,993, Biological Evaluation of Medical Devices, International Standards Organization
14
Sensitization test•Allergic response caused by the activation of complex cellular and humoral immunological mechanisms can occur after either single or multiple exposures
•Animal used: Guinea pig
•Method: Buehler closed-patch test and the Magnusson-Kligman guinea pig maximization (ISO 10993-10)
•If the test material is amenable to intradermal injection, the maximization test is recommended. The closed-patch test is the assay of choice for non-extractable, or when the extract or material may be topically applied
•Induction phase followed by challange phase
13
16
Systemic toxicity •It estimate the potential harmful effects in vivo on target tissues and organs away from the point of contact with either single or multiple exposure to medical devices, biomaterials, and/or their extracts
•Conducted by administering the extracts (polar and nonpolar in most cases) as a single dose to test animals, and the health status of the animals is verified periodically—typically 24, 48 and 72 hours after dosing
•Solvents, should be chosen to yield a maximum extraction of leachable materials for use in the testing
• Animals of choice for the conduct of these tests are mice, rats, or rabbits
14
18
• It may be acute, sub-acute or chronic
• Acute toxicity is considered to be the adverse effects that occur after administration of a single dose or multiple doses of a test sample given within 24 hours
• Subacute toxicity (repeat-dose toxicity) focuses on adverse effects occurring after administration of a single dose or multiple doses of a test sample per day during a period of from 14 to 28 days
• Chronic toxicity tests determine the effects of either single or multiple exposures to medical devices, materials, and/or their extracts during a period of at least 10% of the lifespan of the test animal
Contd...
19
ISO defines the clinical observation descriptors as respiratory, motor activities, convulsion, reflexes, ocular signs, cardiovascular signs, salivation, piloerection, analgesia, muscle tone, gastrointestinal and skin
Contd...RESPONSE DESCRIPTION
Normal, no symptoms No adverse physical symptoms after injection
Slight Slight loss of motor function, slight difficulty breathing, and symptoms of irritation in the abdominal cavity
Moderate Difficulty breathing, loss of motor function, dropping of eyelids, and diarrhea clearly observed
Marked Cyanosis, and trembling, or a sever case of irritation in the abdominal cavity, diarrhea, drooping of the eyelids, and difficulty of breathing are observed
Dead, expired Mouse dies after injection
Genotoxicity
•in vivo genotoxicity tests are carried out if indicated by the chemistry and/or composition of the biomaterial or if in vitro test results indicate potential genotoxicity
•Initially, at least three in vitro assays should be used and two of these assays should utilize mammalian cells
•The initial in vitro assays should cover the three levels of genotoxic effects:
DNA destruction,
Gene mutations, and
Chromosomal aberrations
21
in vivo genotoxicity
tests
chromosomal analysis
mouse spot test
micronucleus test
mouse heritable
translocation assay
mammalian germ cell
cytogenetic assay
22
The most common test is the rodent micronucleus test:
• The in vivo test normally uses mouse bone marrow or
mouse peripheral blood
• Micronuclei, also known as Howell–Jolly bodies, are
generally smooth, round remnants of nuclear
chromatin seen in erythrocytes
• An increase in the frequency of micronucleated
erythrocytes in treated animals is an indication of
induced chromosome damage
23
Micronucleated erythrocytes
24
Implantation test
• Implantation tests assess the local pathological effects on the structure and function of living tissue induced by a sample of a material or final product
• For short-term implantation evaluation out to 12 weeks
• Animals utilized in these studies are mice, rats, guinea pigs, or rabbits
• For longer-term testing in subcutaneous tissue, muscle, or bone • Animals such as rabbits, dogs, sheep, goats, pigs, and
other animals with relatively long life expectancy are suitable
25
Contd...
• Short-term effects are assessed by evaluating tissue
responses to the implant at 1 and 4 weeks following the
procedure
• At least four rabbits per time period are recommended,
and each rabbit is implanted with at least four test and
two negative control materials
• Evaluated responses include inflammatory reactions and
the area thus affected
• If at least two of the four test sites exhibit a significant
response compared with the control sites, an adverse or
positive effect can be assumed
26
Eye irritation test (Draize test)• Local tissue inflammation response to chemicals, without
a systemic immunological component.
• Test animal: Rabbit
• Volume of Extract: 0.1 mL
• Extract is instilled in one eye of each animal, the other
eye receives the control vehicle
• The test and control eyes are assessed for biological
responses at 1, 24, 48, and 72 hours after instillation
• The observation period need not exceed 21 days
27
28
29
SCORE OBSERVED EFFECT
0 Non irritant
0-0.5 Minimal irritant
0.5-2 Mild irritant
2-5 Moderate irritant
5-8 Severe irritant
Contd...
30
Skin irritation test
• Measured by Trans-epithelial Water Loss (TEWL) test
• TEWL measurements are of great importance in
evaluating barrier functionality
• The more perfect the skin protective coat, the higher
the water content and the lower the TEWL
31
Figure 1. Schematic illustration of the barrier function of the stratum corneum. a) healthy skin , b) disturbed skin
• Pyrogens are substances in devices that cause a febrile
reaction
• Bacterial endotoxin contamination is most commonly
associated with such an adverse effect; however,
leachates of materials can cause similar febrile responses
(material-mediated pyrogenicity)
• ISO 10993-11 recommends testing the pyrogenicity
potential of extractable substances derived from material
leaching
Pyrogen testing
33
Number of animals: Three rabbits required; comparison of febrile response in test animals to baseline temperature for evaluation of pyrogenicity potential
Test duration: Test measurement intervals: every 30 minutes for 3 hours
Evaluation: Cutoff for positive febrile response: 0.5°C
If any single animal of the three has a temperature increase above the acceptable range, the test can be continued with 5 additional animals
34
Carcinogenicity
• Carcinogens induce tumors (benign or malignant),
increase their incidence or malignancy, or shorten the
time of tumor occurrence when they are inhaled,
injected, dermally applied, or ingested
• This test determine the tumorigenic potential of
medical devices, materials, and/or their extracts from
either single or multiple exposures
Maurici, et al., 2005, p. 177
35
• Carcinogenicity tests should be conducted only if data
from other sources suggest a tendency for tumor
induction
• The conventional test for carcinogenicity is the long-
term rodent carcinogenicity bioassay requiring 2 years
• Carcinogenicity and chronic toxicity may be studied in a
single experimental study
• To facilitate and reduce the time period for
carcinogenicity testing of biomaterial, the FDA is
exploring the use of transgenic mice carrying the human
prototype c-Ha-ras gene as a bioassay mode for rapid
carcinogenicity testing.
Contd...
36
• The gene, is capable of transforming normal cells into a neoplastic cell following its mutation, confers an unusually high susceptibility to tumor formation in rasH2 transgenic mice
• Various advantages of c-Ha-ras animals are:
Contd...
Mutagen detection within 6 months
Able to detect various non mutagenic carcinogens
More rapid onset and higher incidence of tumors
37
Hemocompatibility
BIOMATERIAL
BLOOD
HUMORAL EFFECTSCELLULAR EFFECTSex: thrombosis, embolism, lysis, and inflammation
ex: activation of the coagulation, kinin, complement, and fibrinolytic systems
Device contact with circulating blood
DIRECT INDIRECTIMPLANTSDrainage catheters, Butterfly needles
Stents, Cardiac valve Blood bag
38
39
Platelets adhesion and aggregation
Thrombosis
• Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system
40
Test article (e.g., tubing or catheter) is implanted in the
jugular veins of two (2) dogs.
The test article is implanted in the jugular vein
The test article are removed and examined for the
presence of thrombi, and the vein is examined for
patency (occlusion)
41
Possible scenarios for blood–materials interactions
42
THANK YOU
43
44
top related